MYGN MYRIAD GENETICS INC

CIK 0000899923 23 ready 8-Ks latest May 5, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 23

Latest filing May 5, 2026, 7:59 PM ET

Top materiality 0.80

Event mix earnings ×12 · leadership ×5 · other ×2

Sentiment 5 pos · 5 neg · 13 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for MYGN

Highest-materiality recent filing

Myriad Genetics Q2 revenue $213.1M (+1% YoY); raises FY2025 revenue guidance

August 5, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

GAAP net loss $330.5M ($3.57/share) includes $316.7M impairment; adjusted EPS $0.05.
Hereditary cancer testing revenue +9% YoY in Oncology; MyRisk with RiskScore volume +14%.

Read filing →

May 5, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Myriad Genetics Q1 revenue $200.4M, GAAP net loss $34.1M; reiterates FY guidance

GAAP net loss $34.1M ($0.36/sh); adjusted loss $0.09/sh; adjusted EBITDA negative $4.5M.
February 23, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Myriad Genetics Q4 2025 revenue $209.8M, net loss $7.9M; reiterates 2026 guidance

GAAP net loss $7.9M ($0.08 loss per share); adjusted EPS $0.04.
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Myriad Genetics prelim Q4 revenue $207-209M, FY25 $822-824M; FY26 guidance $860-880M

Preliminary Q4 2025 total revenue $207-209M; full year 2025 revenue $822-824M.
November 4, 2025, 6:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

Myriad Genetics Q3 revenue $205.7M (-4% YoY); adjusted EPS $0.00; reaffirms FY2025 guidance

Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M headwinds (UNH GeneSight loss, EndoPredict divestiture).
November 3, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Myriad Genetics Q3 revenue $205.7M (-4% YoY); GAAP net loss $0.29/sh, adj EPS $0.00; FY guidance reiterated

Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M in headwinds from UNH GeneSight coverage loss and EndoPredict divestiture.
August 18, 2025, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01

Myriad Genetics appoints Ben Wheeler as CFO; reaffirms FY2025 guidance

Scott Leffler stepped down as CFO effective Aug 15, 2025; will consult through Sept 2, 2025.
August 5, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Myriad Genetics Q2 revenue $213.1M (+1% YoY); raises FY2025 revenue guidance

GAAP net loss $330.5M ($3.57/share) includes $316.7M impairment; adjusted EPS $0.05.
July 31, 2025, 7:59 PM ET debt materiality 0.70 neutral item 1.01 item 2.03 item 8.01 item 9.01 ◈ Debt Financings

Myriad Genetics closes $200M credit facility with OrbiMed; $125M funded

Five-year senior secured term loan; $125M funded at closing, $75M delayed draw available through June 2027.
May 6, 2025, 7:59 PM ET earnings materiality 0.78 negative item 2.02 item 9.01

Myriad Genetics Q1 revenue down 3% to $196M; net loss of $0.1M; lowers FY2025 guidance

GAAP net loss $0.1M ($0.00 EPS); adjusted EPS $(0.03). Revenue of $196M declined 3% YoY.
February 24, 2025, 6:59 PM ET leadership materiality 0.80 positive item 2.02 item 5.02 item 7.01 item 9.01 ◈ executive_change ×3

Myriad Genetics: CEO succession plan; Q4 revenue $211M (+7%), FY 2024 revenue $838M (+11%)

CEO Paul J. Diaz resigns effective April 30, 2025; COO Samraat S. Raha appointed President, CEO, and Board member.
January 15, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Myriad Genetics reports preliminary Q4 rev $209-211M, FY2025 adj EPS guidance $0.07-0.11

Q4 2024 preliminary revenue $209-211M (+6-7% YoY); GAAP diluted loss $(0.72)-(0.62)/share; adj EPS $0.03-$0.04.
November 7, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Myriad Genetics Q3 revenue +11% to $213M, adj EPS $0.06; UNH to drop GeneSight coverage Jan 2025

Q3 revenue $213M (+11% YoY); GAAP net loss $22.1M improved from $61.3M loss; adj EBITDA $14.1M vs $1.4M.
September 4, 2024, 7:59 PM ET other material materiality 0.65 negative item 7.01 item 9.01

Myriad Genetics discontinues part two of GeneSight study; control group deemed unreliable

Part one (April 2024) showed 29% drop in all-cause hospitalizations and 39% drop in psychiatric-related hospitalizations 180 days post-GeneSight.
August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Myriad Genetics Q2 revenue $212M (+15% YoY); raises FY2024 guidance, adjusted EPS $0.05

Revenue $212M (+15% YoY); GAAP EPS $(0.41) vs $(1.42) YoY; adjusted EPS $0.05 vs $(0.08).
May 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Myriad Genetics Q1 revenue $202M (+12% YoY), positive adjusted EBITDA $4M, reiterates FY guidance

Q1 revenue $202.2M (+12% YoY); GAAP net loss narrowed to $26M from $55M.

Executive changes

Role change

Samraat S. Raha

President and Chief Executive Officer

MYGN · MYRIAD GENETICS INC

Effective: 2025-04-30
Filed: February 24, 2025, 6:59 PM ET

the Board appointed Samraat S. Raha, the Company's Chief Operating Officer, to succeed Mr. Diaz as its President and Chief Executive Officer on the Effective Date.

Appointed

Samraat S. Raha

Director

MYGN · MYRIAD GENETICS INC

Effective: 2025-04-30
Filed: February 24, 2025, 6:59 PM ET

the Board also appointed Mr. Raha to the Board to serve as a Class II director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders as of the Effective Date to fill the vacancy on the Board that will be created by Mr. Diaz’ resignation.

Departed

Paul J. Diaz

President and Chief Executive Officer

MYGN · MYRIAD GENETICS INC

Effective: 2025-04-30
Successor: Samraat S. Raha
Filed: February 24, 2025, 6:59 PM ET

Paul J. Diaz, the Company’s President and Chief Executive Officer, announced on February 24, 2025 that he will step down from those positions, and resign from the Company’s Board of Directors (the “Board”), on April 30, 2025

Earnings & guidance

2026-Q1 EPS reported -$0.36 filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event earnings

5 positive 5 negative 13 neutral

source · MYGN on sec.gov